ArticleAnalytical and bioanalytical chemistry2013
A microfluidic electrochemiluminescent device for detecting cancer biomarker proteins.
Article in Analytical and bioanalytical chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 98 citations in OpenAlex.
- Electrochemical liquid biopsy across cancer care pathway.The journal of liquid biopsy · 2026Review
- Microfluidics as a promising technology for personalized medicine.BioImpacts : BI · 2025Review
- Cutting-edge 3D printing in immunosensor design for early cancer detection.Mikrochimica acta · 2024Review
- Modulating the interaction of graphenic substrates with human interleukin-6 and its monoclonal antibody: a study by Raman images.RSC advances · 2023Article
- Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice.Proteomes · 2023Review
- Modular microfluidic system for on-chip extraction, preconcentration and detection of the cytokine biomarker IL-6 in biofluid.Scientific reports · 2022Article
- Multiplexed Prostate Cancer Companion Diagnostic Devices.Sensors (Basel, Switzerland) · 2021Review
- Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis.Frontiers in oncology · 2021Review
- 3D-Printed Immunosensor Arrays for Cancer Diagnostics.Sensors (Basel, Switzerland) · 2020Review
- Recent Advances in Microfluidic Paper-Based Analytical Devices toward High-Throughput Screening.Molecules (Basel, Switzerland) · 2020Review
- Recent Progress of Biomarker Detection Sensors.Research (Washington, D.C.) · 2020Review
- Sensitive Raman detection of human recombinant interleukin-6 mediated by DCDR/GERS hybrid platforms.RSC advances · 2019Article
- Automated 4-Sample Protein Immunoassays using 3D-Printed Microfluidics.Analytical methods : advancing methods and applications · 2018Article
- Automated 3D-Printed Microfluidic Array for Rapid Nanomaterial-Enhanced Detection of Multiple Proteins.Analytical chemistry · 2018Article
- Nanomaterial-based biosensors for detection of prostate specific antigen.Mikrochimica acta · 2017Review
- Spotlight on Biomimetic Systems Based on Lyotropic Liquid Crystal.Molecules (Basel, Switzerland) · 2017Review
- Biomolecular engineering for nanobio/bionanotechnology.Nano convergence · 2017Review
- On-Chip Fluorescent Labeling using Reversed-phase Monoliths and Microchip Electrophoretic Separations of Selected Preterm Birth Biomarkers.Analytical methods : advancing methods and applications · 2016Article
- A Microchip for Integrated Single-Cell Gene Expression Profiling and Genotoxicity Detection.Sensors (Basel, Switzerland) · 2016Article
- 3D-printed supercapacitor-powered electrochemiluminescent protein immunoarray.Biosensors & bioelectronics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
We describe an electrochemiluminescence (ECL) immunoarray incorporated into a prototype microfluidic device for highly sensitive protein detection and apply this system to accurate, sensitive measurements of prostate-specific antigen (PSA) and interleukin-6 (IL-6) in serum. The microfluidic system employed three molded polydimethylsiloxane (PDMS) channels on a conductive pyrolytic graphite chip (2.5 × 2.5 cm) inserted into a machined chamber and interfaced with a pump, switching valve, and sample injector. Each of the three PDMS channels encompasses three 3 μL analytical wells. Capture-antibody-decorated single-wall carbon nanotube forests are fabricated in the bottom of the wells. The antigen is captured by these antibodies on the well bottoms. Then, a RuBPY-silica-secondary antibody (Ab2) label is injected to bind to antigen on the array, followed by injection of sacrificial reductant tripropylamine (TPrA) to produce ECL. For detection, the chip is placed into an open-top ECL measuring cell, and the channels are in contact with electrolyte in the chamber. Potential applied at 0.95 V versus Ag/AgCl oxidizes TPrA to produce ECL by redox cycling the RuBPY species in the particles, and ECL light is measured by a charge-coupled device camera. This approach achieved ultralow detection limits of 100 fg mL(-1) for PSA (9 zeptomole) and 10 fg mL(-1) (1 zeptomole) for IL-6 in calf serum, a 10-25-fold improvement of a similar non-microfluidic array. PSA and IL-6 in synthetic cancer patient serum samples were detected in 1.1 h and results correlated well with single-protein enzyme-linked immunosorbent assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.